AK1967 (Invobenitug also known as Procizumab); Placebo
Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Invobenitug Also Known as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations.
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 90 чел. во всех странах исследования.
- Центров в реестре: 2 в одном городе. Список — ниже на странице.
- Плановое окончание — 12.2026.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 32
Критерии включения
- Signed informed consent.
- Diagnosis of CS based on the following entry criteria:
- Need for ongoing vasopressors and/or inotropes to maintain a MAP ≥ 65 mmHg or SBP ≥ 90 mmHg
- Lactate ≥ 2.0 mmol/L
- High DPP3 concentration ≥ 30 ng/mL
- Etiology of CS must be one of the following: ACS, septic (according to SEPSIS 3 criteria) or adHF origin
Критерии невключения
- Patients who will be receiving vasopressors and/or inotropes for more than 16 hours prior to receiving the IMP.
- Patients being longer than 24 hours in the ICU at the time of randomization.
- Patients below the age of 18 or above 80 years.
- Patients receiving Ang II and/or levosimendan
- Patients with known allergies or hypersensitivity to the IMP or its excipients or any related medication.
- Stroke or transient ischemic attack within the last 3 months.
- SCAI Shock Stage E.
- Reduced life expectancy of less than 6 months due to comorbidities (prior to shock onset).
- Very severe frailty, or moribund condition or presence of clinical circumstances indicating imminent death.
- Only for Part 1: Patients on cannula-based MCS (including VV and VA-ECMO, impella or left ventricular assist device of any type (excluding IABP)) or on renal replacement therapy. Patients who are treated by impella and/or ECMO but have no evidence of hemolysis during screening can be enrolled in the trial.
- Patients exceeding a maximum body weight of 120 kg (EU, Armenia, Serbia) and 150 kg (US).
- CPR lasting more than 15 minutes and/or the patient is not conscious at randomization.
- Primary hypertrophic or restrictive cardiomyopathy or congenital heart disease or systemic illness known to be associated with infiltrative heart disease.
- Pericardial constriction.
- Sustained SBP > 120 mmHg during the hour prior to randomization.
- Known severe chronic liver disease (Model for End-Stage Liver Disease (MELD) Score >30), known severe chronic pulmonary disease (including COPD classification GOLD4 and/or chronic oxygen therapy and/or restrictive chronic pulmonary failure and/or severe interstitial lung disease), known severe thyroid disease, known CKD with eGFR <20 ml/min/1.73 m2 or chronic dialysis.
- Patients with untreated sepsis.
- Patients with valvular heart diseases as the primary cause of cardiogenic shock.
- Other known causes of shock, namely
- Hypovolemia
- Hemorrhage
- Anaphylaxis
- Intoxication (e.g., drug-induced shock)
- Dynamic left ventricular outflow tract obstruction
- isolated right heart failure, including cardiac tamponade and/or pulmonary embolism
- Known mechanical complications due to myocardial infarction, including papillary muscle rupture, ventricular septal rupture, free wall rupture
- Inappropriate pacing or shock resulting from ICD malfunction
- Patients who have severe immune suppression: recent (<3 months) chemotherapy and/or severe neutropenia (neutrophile count <500 cells/mm3) and/or chronic high glucocorticoid dose (≥0.5 mg/kg per day of prednisone equivalent) and/or recent (<3 months) organ transplantation.
- Patients who have undergone any form of surgery in the last 7 days, except 1) minor surgeries such as cosmetic surgeries, skin surgery, dental surgery and impella implantation 2) surgery for peritonitis with adequate source control, which are allowed.
- Women who are pregnant or breastfeeding.
- Patients who are currently enrolled in another clinical trial, or who have participated in such trials within one month prior to randomization.
- Any reason that the investigator anticipates that the patient will be unable to complete the protocol or its required procedures (US only).
Источник: ClinicalTrials.gov, NCT06832722 · запись обновлена в реестре 14 сентября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- Reported number of treatment-emergent adverse events from start of Invobenitug administration up until the last follow-up visit after Invobenitug administration — 30 days
Цель исследования
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of invobenitug are evaluated to define the optimum phase 2 dose (P2D) of invobenitug.
Где проходит
2 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06832722 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.